Technology
Biomarkers
Discovery of a biomarker for cancer detection and monitoring the efficacy of anti-cancer drugs: AF300.
As a result of metabolomic research in oncology, a new metabolite, named AF300, has been identified that is present in various tumours and involved in tumour progression.
A patent related to its properties and identification was granted in June 2011.
All the steps leading to the production of this metabolite have been identified and it has been shown that its production is inhibited by different anti-cancer drugs such as tamoxifen, and AF122, the lead anti-cancer drug candidate of the product portfolio of Affichem.
The economic interest of AF300 is two-fold: it constitutes both a diagnostic marker of cancer and a prognostic marker to monitor the efficacy of treatments.
Affichem is focusing on the development of diagnostic tools in order to position AF300 as a future partner-product in terms of the development and monitoring of the clinical efficacy of AF122 in cancer treatment.
AFFINSPI project.
The project is coordinated by AFFICHEM and involved the BERTIN Pharma company and 2 teams of INSERM UMR1037 and U563 from Toulouse (directed by Dr. Marc Poirot and Prof. Georges Delsol).
In the context where the cost of developing a new therapeutic product is becoming higher and the need for targeted therapies increasingly important, the development of biomarkers offers promise for reducing costs and development time for drugs and tailor treatments for individual patients. The AFFINSPI project aims to develop a first generation of products for the R&D and diagnostic markets. These products, based on the identification of a new biomarker of tumor progression, should help in the diagnosis and recurrence of certain cancers like breast cancer.
http://www.competitivite.gouv.fr/spip.php?article581
http://www.cancerbiosante.fr/Le-projet-AFFINSPI-labellise-par.html